Wolters Kluwer appoints Greg Samios as CEO of Health division
Wolters Kluwer (WTKWY) has appointed Greg Samios as the new CEO of its Health division, effective June 1, 2025. Samios, who brings over 25 years of healthcare experience, succeeds Stacey Caywood, who became a Member of the Executive Board on May 15, 2025.
As Executive Vice President of the Health division's largest business units, Samios has led growth in clinical decision support products like UpToDate and Medi-Span. He spearheaded the integration of generative AI into healthcare products and strengthened partnerships with digital health companies. His previous roles include Executive VP of Legal & Regulatory U.S. at Wolters Kluwer and health-focused positions at Elsevier.
Wolters Kluwer (WTKWY) ha nominato Greg Samios nuovo CEO della divisione Health, a partire dal 1° giugno 2025. Samios, con oltre 25 anni di esperienza nel settore sanitario, succede a Stacey Caywood, che il 15 maggio 2025 è diventata membro del Consiglio Esecutivo.
In qualità di Vicepresidente Esecutivo delle principali unità di business della divisione Health, Samios ha guidato la crescita di prodotti per il supporto decisionale clinico come UpToDate e Medi-Span. Ha promosso l'integrazione dell'intelligenza artificiale generativa nei prodotti sanitari e rafforzato le collaborazioni con aziende digitali nel settore salute. In precedenza ha ricoperto il ruolo di Vicepresidente Esecutivo Legale e Regolatorio negli Stati Uniti per Wolters Kluwer e posizioni focalizzate sulla salute presso Elsevier.
Wolters Kluwer (WTKWY) ha designado a Greg Samios como nuevo CEO de su división de Salud, con efecto a partir del 1 de junio de 2025. Samios, con más de 25 años de experiencia en el sector sanitario, sucede a Stacey Caywood, quien el 15 de mayo de 2025 pasó a ser miembro de la Junta Ejecutiva.
Como Vicepresidente Ejecutivo de las unidades de negocio más grandes de la división de Salud, Samios ha impulsado el crecimiento de productos de soporte para decisiones clínicas como UpToDate y Medi-Span. Lideró la integración de la inteligencia artificial generativa en productos sanitarios y fortaleció las alianzas con empresas de salud digital. Anteriormente, desempeñó cargos como Vicepresidente Ejecutivo Legal y Regulatorio en EE. UU. para Wolters Kluwer y ocupó puestos enfocados en salud en Elsevier.
Wolters Kluwer (WTKWY)는 2025년 6월 1일부로 헬스케어 부문의 신임 CEO로 Greg Samios를 임명했습니다. 25년 이상의 헬스케어 경험을 가진 Samios는 2025년 5월 15일 경영위원회 멤버가 된 Stacey Caywood의 뒤를 잇습니다.
헬스케어 부문 내 가장 큰 사업부의 수석 부사장으로서 Samios는 UpToDate와 Medi-Span 같은 임상 의사결정 지원 제품의 성장을 이끌었습니다. 생성형 AI를 헬스케어 제품에 통합하고 디지털 헬스 기업들과의 파트너십을 강화하는 데 앞장섰습니다. 이전에는 Wolters Kluwer 미국 법률 및 규제 부문 수석 부사장과 Elsevier에서 헬스케어 관련 직책을 역임했습니다.
Wolters Kluwer (WTKWY) a nommé Greg Samios nouveau PDG de sa division Santé, à compter du 1er juin 2025. Samios, qui possède plus de 25 ans d'expérience dans le secteur de la santé, succède à Stacey Caywood, devenue membre du Conseil exécutif le 15 mai 2025.
En tant que vice-président exécutif des plus grandes unités commerciales de la division Santé, Samios a conduit la croissance des produits d'aide à la décision clinique tels qu'UpToDate et Medi-Span. Il a piloté l'intégration de l'IA générative dans les produits de santé et renforcé les partenariats avec des entreprises de santé numérique. Il a auparavant occupé les postes de vice-président exécutif juridique et réglementaire aux États-Unis chez Wolters Kluwer et des fonctions axées sur la santé chez Elsevier.
Wolters Kluwer (WTKWY) hat Greg Samios zum neuen CEO seiner Gesundheitsdivision ernannt, wirksam ab dem 1. Juni 2025. Samios, der über 25 Jahre Erfahrung im Gesundheitswesen mitbringt, folgt auf Stacey Caywood, die am 15. Mai 2025 Mitglied des Vorstandes wurde.
Als Executive Vice President der größten Geschäftsbereiche der Gesundheitsdivision leitete Samios das Wachstum von klinischen Entscheidungshilfen wie UpToDate und Medi-Span. Er führte die Integration generativer KI in Gesundheitsprodukte an und stärkte Partnerschaften mit digitalen Gesundheitsunternehmen. Zuvor war er Executive VP für Recht und Regulierung in den USA bei Wolters Kluwer sowie in gesundheitsbezogenen Positionen bei Elsevier tätig.
- Appointment of an experienced internal candidate with 25+ years of healthcare expertise
- Track record of driving growth in key products (UpToDate and Medi-Span)
- Experience in implementing generative AI solutions in healthcare products
- Strong background in both health and legal sectors within Wolters Kluwer
- None.
PRESS RELEASE
Wolters Kluwer appoints Greg Samios as CEO of Health division
Experienced healthcare executive has track record of driving innovation and delivering results
Alphen aan den Rijn — May 29, 2025 — Wolters Kluwer, a global leader in information solutions, software, and services for professionals, has named Greg Samios as Chief Executive Officer of its Health division, effective June 1. Samios succeeds Stacey Caywood, who became a Member of the Executive Board of Wolters Kluwer on May 15, 2025.
A seasoned healthcare executive with more than twenty-five years of experience, Samios has served as Executive Vice President of the Health division’s two largest business units, Clinical Effectiveness and Health Learning, Research, and Practice. While a Health division leader, Samios has driven growth in Wolters Kluwer’s leading clinical decision support and clinical drug information products, UpToDate and Medi-Span. He also led the introduction of generative AI into the company’s healthcare products and solidified partnerships with leading digital health companies.
In a prior role at Wolters Kluwer, Samios served as Executive Vice President of the Legal & Regulatory U.S. business. His career experience before joining Wolters Kluwer included several health-focused positions at Elsevier spanning more than ten years. He earned a Master of Business Administration from Duke University Fuqua School of Business and graduated with a B.S. and M.S. in Engineering from the University of Rochester.
“We are delighted to name Greg Samios as the new CEO of Wolters Kluwer Health,” said Nancy McKinstry, Chief Executive Officer and Chair of the Executive Board for Wolters Kluwer. “Our large, global Health division requires an experienced leader to continue driving innovation and adapting to market challenges. We are confident that Greg has the right combination of experience and passion to deliver on our strategy and drive incremental value for our customers and growth for our business.”
Wolters Kluwer Health supports professionals across healthcare with trusted advanced technology, evidence-based solutions, research, and life-long learning.
###
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2024 annual revenues of
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.
| Media | Investor/Analyst |
| Stefan Kloet | Meg Geldens |
| Associate Director | Vice President |
| Global Communications | Investor Relations |
| press@wolterskluwer.com | ir@wolterskluwer.com |
| t: +316 1233 657 | |
| Andre Rebelo | |
| Wolters Kluwer Health | |
| Director, External Communications | |
| andre.rebelo@wolterskluwer.com | |
| t: +1 781 392 2411 | |
Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
FAQ
Who is the new CEO of Wolters Kluwer Health division?
What is Greg Samios' experience before becoming WTKWY Health division CEO?
What are Greg Samios' key achievements at Wolters Kluwer Health?
Who did Greg Samios replace as CEO of WTKWY Health division?
